Ramalingam SS - Search Results

1

Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.

McCall NS, Janopaul-Naylor JR, McGinnis HS, Kesarwala AH, Tian S, Stokes WA, Shelton JW, Steuer CE, Carlisle JW, Leal TA, Ramalingam SS, Bradley JD, Higgins KA. McCall NS, et al. Among authors: ramalingam ss. Cancer. 2023 Dec 1;129(23):3713-3723. doi: 10.1002/cncr.34915. Epub 2023 Jun 24. Cancer. 2023. PMID: 37354070

2

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.

Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS. Belani CP, et al. Among authors: ramalingam ss. Cancer. 2008 Nov 1;113(9):2512-7. doi: 10.1002/cncr.23902. Cancer. 2008. PMID: 18816622 Free article. Clinical Trial.

3

Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.

Pakkala S, Ramalingam SS. Pakkala S, et al. Among authors: ramalingam ss. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003. Clin Lung Cancer. 2009. PMID: 19362942 Review.

4

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Owonikoko TK, et al. Among authors: ramalingam ss. Int J Cancer. 2010 Feb 1;126(3):743-55. doi: 10.1002/ijc.24759. Int J Cancer. 2010. PMID: 19621389 Free PMC article.

5

The role of cetuximab in the management of non-small-cell lung cancer.

Owonikoko TK, Sun SY, Ramalingam SS. Owonikoko TK, et al. Among authors: ramalingam ss. Clin Lung Cancer. 2009 Jul;10(4):230-8. doi: 10.3816/CLC.2009.n.031. Clin Lung Cancer. 2009. PMID: 19632939 Review.

6

Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.

Mok TS, Ramalingam SS. Mok TS, et al. Among authors: ramalingam ss. Cancer. 2009 Nov 15;115(22):5143-54. doi: 10.1002/cncr.24563. Cancer. 2009. PMID: 19658185 Free article. Review.

7

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.

Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M, Belani CP. Ramalingam SS, et al. Cancer. 2010 Mar 1;116(5):1344-9. doi: 10.1002/cncr.24753. Cancer. 2010. PMID: 20082454 Free article. Clinical Trial.

8

Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.

Owonikoko TK, Ramalingam SS, Belani CP. Owonikoko TK, et al. Among authors: ramalingam ss. Clin Cancer Res. 2010 May 1;16(9):2496-504. doi: 10.1158/1078-0432.CCR-09-2328. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388843

9

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Ramalingam SS, et al. J Thorac Oncol. 2010 Aug;5(8):1279-84. doi: 10.1097/JTO.0b013e3181e2fcb0. J Thorac Oncol. 2010. PMID: 20559150 Free PMC article. Clinical Trial.

10

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR. Ramalingam SS, et al. Cancer. 2010 Aug 15;116(16):3903-9. doi: 10.1002/cncr.25264. Cancer. 2010. PMID: 20564143 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

367 results

Search Page